Generating patient-specific induced pluripotent stem cells-derived cardiomyocytes for the treatment of cardiac diseases

Bibliography

• Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 2007;131(5):861-72
   PubMed Web of Science ®Google Scholar
• Schenke-Layland K, Rhodes KE, Angelis E, et al. Reprogrammed mouse fibroblasts differentiate into cells of the cardiovascular and hematopoietic lineages. Stem Cells 2008;26(6):1537-46
   PubMed Web of Science ®Google Scholar
• Narazaki G, Uosaki H, Teranishi M, et al. Directed and systematic differentiation of cardiovascular cells from mouse induced pluripotent stem cells. Circulation 2008;118(5):498-506
   PubMed Web of Science ®Google Scholar
• Zhang J, Wilson GF, Soerens AG, et al. Functional cardiomyocytes derived from human induced pluripotent stem cells. Circ Res 2009;104(4):e30-41
   PubMed Web of Science ®Google Scholar
• Laflamme MA, Chen KY, Naumova AV, et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 2007;25(9):1015-24
   PubMed Web of Science ®Google Scholar
• Yang L, Soonpaa MH, Adler ED, et al. Human cardiovascular progenitor cells develop from a KDR+ embryonic-stem-cell-derived population. Nature 2008;453(7194):524-8
   PubMed Web of Science ®Google Scholar
• Kehat I, Khimovich L, Caspi O, et al. Electromechanical integration of cardiomyocytes derived from human embryonic stem cells. Nat Biotechnol 2004;22(10):1282-9
   PubMed Web of Science ®Google Scholar
• Xu C, Police S, Rao N, Carpenter MK. Characterization and enrichment of cardiomyocytes derived from human embryonic stem cells. Circ Res 2002;91(6):501-8
   PubMed Web of Science ®Google Scholar
• Zhu WZ, Van Biber B, Laflamme MA. Methods for the derivation and use of cardiomyocytes from human pluripotent stem cells. Methods Mol Biol 2011;767:419-31
   PubMedGoogle Scholar
• Burridge PW, Matsa E, Shukla P, et al. Chemically defined generation of human cardiomyocytes. Nat Methods 2014;11(8):855-60
   PubMed Web of Science ®Google Scholar
• Zhang M, Schulte JS, Heinick A, et al. Universal cardiac induction of human pluripotent stem cells in 2D and 3D formats - implications for in-vitro maturation. Stem Cells 2015;33(5):1456-69
   PubMed Web of Science ®Google Scholar
• Ren Y, Lee MY, Schliffke S, et al. Small molecule Wnt inhibitors enhance the efficiency of BMP-4-directed cardiac differentiation of human pluripotent stem cells. J Mol Cell Cardiol 2011;51(3):280-7
   PubMed Web of Science ®Google Scholar
• Lian X, Hsiao C, Wilson G, et al. Robust cardiomyocyte differentiation from human pluripotent stem cells via temporal modulation of canonical Wnt signaling. Proc Natl Acad Sci USA 2012;109(27):E1848-57
   PubMed Web of Science ®Google Scholar
• Karakikes I, Senyei GD, Hansen J, et al. Small molecule-mediated directed differentiation of human embryonic stem cells toward ventricular cardiomyocytes. Stem Cells Transl Med 2014;3(1):18-31
   PubMed Web of Science ®Google Scholar
• Weng Z, Kong CW, Ren L, et al. A simple, cost-effective but highly efficient system for deriving ventricular cardiomyocytes from human pluripotent stem cells. Stem Cells Dev 2014;23(14):1704-16
   PubMed Web of Science ®Google Scholar
• Dubois NC, Craft AM, Sharma P, et al. SIRPA is a specific cell-surface marker for isolating cardiomyocytes derived from human pluripotent stem cells. Nat Biotechnol 2011;29(11):1011-18
   PubMed Web of Science ®Google Scholar
• Tohyama S, Hattori F, Sano M, et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 2013;12(1):127-37
   PubMed Web of Science ®Google Scholar
• Lundy SD, Zhu WZ, Regnier M, Laflamme MA. Structural and functional maturation of cardiomyocytes derived from human pluripotent stem cells. Stem Cells Dev 2013;22(14):1991-2002
   PubMed Web of Science ®Google Scholar
• Kim C, Wong J, Wen J, et al. Studying arrhythmogenic right ventricular dysplasia with patient-specific iPSCs. Nature 2013;494(7435):105-10
   PubMed Web of Science ®Google Scholar
• Sinnecker D, Goedel A, Dorn T, et al. Modeling long-QT syndromes with iPS cells. J Cardiovasc Transl Res 2013;6(1):31-6
   PubMed Web of Science ®Google Scholar
• Moretti A, Bellin M, Welling A, et al. Patient-specific induced pluripotent stem-cell models for long-QT syndrome. N Engl J Med 2010;363(15):1397-409
   PubMed Web of Science ®Google Scholar
• Itzhaki I, Maizels L, Huber I, et al. Modelling the long QT syndrome with induced pluripotent stem cells. Nature 2011;471(7337):225-9
   PubMed Web of Science ®Google Scholar
• Terrenoire C, Wang K, Tung KW, et al. Induced pluripotent stem cells used to reveal drug actions in a long QT syndrome family with complex genetics. J Gen Physiol 2013;141(1):61-72
   PubMed Web of Science ®Google Scholar
• Yazawa M, Hsueh B, Jia X, et al. Using induced pluripotent stem cells to investigate cardiac phenotypes in Timothy syndrome. Nature 2011;471(7337):230-4
   PubMed Web of Science ®Google Scholar
• Carvajal-Vergara X, Sevilla A, D’Souza SL, et al. Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome. Nature 2010;465(7299):808-12
   PubMed Web of Science ®Google Scholar
• Lan F, Lee AS, Liang P, et al. Abnormal calcium handling properties underlie familial hypertrophic cardiomyopathy pathology in patient-specific induced pluripotent stem cells. Cell Stem Cell 2013;12(1):101-13
   PubMed Web of Science ®Google Scholar
• Lin B, Li Y, Han L, et al. Modeling and studying mechanism of dilated cardiomyopathy using induced pluripotent stem cells derived from Duchenne Muscular Dystrophy (DMD) patients. Dis Model Mech 2015;8(5):457-66
   PubMed Web of Science ®Google Scholar
• Gramlich M, Pane LS, Zhou Q, et al. Antisense-mediated exon skipping: a therapeutic strategy for titin-based dilated cardiomyopathy. EMBO Mol Med 2015;7(5):562-76
   PubMed Web of Science ®Google Scholar
• Wang G, McCain ML, Yang L, et al. Modeling the mitochondrial cardiomyopathy of Barth syndrome with induced pluripotent stem cell and heart-on-chip technologies. Nat Med 2014;20(6):616-23
   PubMed Web of Science ®Google Scholar
• Karakikes I, Stillitano F, Nonnenmacher M, et al. Correction of human phospholamban R14del mutation associated with cardiomyopathy using targeted nucleases and combination therapy. Nat Commun 2015;6:6955
   PubMed Web of Science ®Google Scholar
• Sun N, Yazawa M, Liu J, et al. Patient-specific induced pluripotent stem cells as a model for familial dilated cardiomyopathy. Sci Transl Med 2012;4(130):130ra47
   PubMed Web of Science ®Google Scholar
• Liang P, Lan F, Lee AS, et al. Drug screening using a library of human induced pluripotent stem cell-derived cardiomyocytes reveals disease-specific patterns of cardiotoxicity. Circulation 2013;127(16):1677-91
   PubMed Web of Science ®Google Scholar
• Navarrete EG, Liang P, Lan F, et al. Screening drug-induced arrhythmia [corrected] using human induced pluripotent stem cell-derived cardiomyocytes and low-impedance microelectrode arrays. Circulation 2013;128(11 Suppl 1):S3-13
   PubMed Web of Science ®Google Scholar
• Nozaki Y, Honda Y, Tsujimoto S, et al. Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation. Toxicol Appl Pharmacol 2014;278(1):72-7
   PubMed Web of Science ®Google Scholar
• Wang Y, Liang P, Lan F, et al. Genome editing of isogenic human induced pluripotent stem cells recapitulates long QT phenotype for drug testing. J Am Coll Cardiol 2014;64(5):451-9
   PubMed Web of Science ®Google Scholar
• Hajjar RJ, Hulot JS. Modeling CVD in human pluripotent cells by genome editing. J Am Coll Cardiol 2014;64(5):460-2
   PubMed Web of Science ®Google Scholar
• Rapti K, Stillitano F, Karakikes I, et al. Effectiveness of gene delivery systems for pluripotent and differentiated cells. Mol Ther Methods Clin Dev 2015;2:14067
   PubMed Web of Science ®Google Scholar
• Merkert S, Khan K, Haase A, et al. Efficient ZFN-based gene inactivation in transgenic human iPS cells as a model for gene editing in patient-specific cells. J Stem Cells Regen Med 2010;6(2):118
   Google Scholar
• Hockemeyer D, Wang H, Kiani S, et al. Genetic engineering of human pluripotent cells using TALE nucleases. Nat Biotechnol 2011;29(8):731-4
   PubMed Web of Science ®Google Scholar
• Miller JC, Tan S, Qiao G, et al. A TALE nuclease architecture for efficient genome editing. Nat Biotechnol 2011;29(2):143-8
   PubMed Web of Science ®Google Scholar
• Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science 2012;337(6096):816-21
   PubMed Web of Science ®Google Scholar
• Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science 2014;346(6213):1258096
   PubMed Web of Science ®Google Scholar
• Frock RL, Hu J, Meyers RM, et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases. Nat Biotechnol 2015;33(2):179-86
   PubMed Web of Science ®Google Scholar
• Tan EP, Li Y, Del Castillo Velasco-Herrera M, et al. Off-target assessment of CRISPR-Cas9 guiding RNAs in human iPS and mouse ES cells. Genesis 2015;53(2):225-36
   PubMed Web of Science ®Google Scholar
• Maeder ML, Linder SJ, Cascio VM, et al. CRISPR RNA-guided activation of endogenous human genes. Nat Methods 2013;10(10):977-9
   PubMed Web of Science ®Google Scholar
• Gilbert LA, Horlbeck MA, Adamson B, et al. Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation. Cell 2014;159(3):647-61
   PubMed Web of Science ®Google Scholar
• Li M, Suzuki K, Kim NY, et al. A cut above the rest: targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 2014;289(8):4594-9
   PubMed Web of Science ®Google Scholar
• Garbern JC, Lee RT. Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 2013;12(6):689-98
   PubMed Web of Science ®Google Scholar
• Kim J, Shapiro L, Flynn A. The clinical application of mesenchymal stem cells and cardiac stem cells as a therapy for cardiovascular disease. Pharmacol Ther 2015;151:8-15
   PubMed Web of Science ®Google Scholar
• Karantalis V, Hare JM. Use of mesenchymal stem cells for therapy of cardiac disease. Circ Res 2015;116(8):1413-30
   PubMed Web of Science ®Google Scholar
• Wehman B, Kaushal S. The emergence of stem cell therapy for patients with congenital heart disease. Circ Res 2015;116(4):566-9
   PubMed Web of Science ®Google Scholar
• Ishigami S, Ohtsuki S, Tarui S, et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 2015;116(4):653-64
   PubMed Web of Science ®Google Scholar
• Vrtovec B, Poglajen G, Sever M, et al. CD34+ stem cell therapy in nonischemic dilated cardiomyopathy patients. Clin Pharmacol Ther 2013;94(4):452-8
   PubMed Web of Science ®Google Scholar
• Madonna R, Ferdinandy P, De Caterina R, et al. Recent developments in cardiovascular stem cells. Circ Res 2014;115(12):e71-8
   PubMed Web of Science ®Google Scholar
• Chong JJ, Yang X, Don CW, et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 2014;510(7504):273-7
   PubMed Web of Science ®Google Scholar
• Hastings CL, Roche ET, Ruiz-Hernandez E, et al. Drug and cell delivery for cardiac regeneration. Adv Drug Deliv Rev 2015;84:85-106
   PubMed Web of Science ®Google Scholar
• Song G, Li X, Shen Y, et al. Transplantation of iPSc restores cardiac function by promoting angiogenesis and ameliorating cardiac remodeling in a post-infarcted swine model. Cell Biochem Biophys 2014. [Epub ahead of print]
   Web of Science ®Google Scholar
• Mauritz C, Martens A, Rojas SV, et al. Induced pluripotent stem cell (iPSC)-derived Flk-1 progenitor cells engraft, differentiate, and improve heart function in a mouse model of acute myocardial infarction. Eur Heart J 2011;32(21):2634-41
   PubMed Web of Science ®Google Scholar
• Yan B, Abdelli LS, Singla DK. Transplanted induced pluripotent stem cells improve cardiac function and induce neovascularization in the infarcted hearts of db/db mice. Mol Pharm 2011;8(5):1602-10
   PubMed Web of Science ®Google Scholar
• Xiong Q, Ye L, Zhang P, et al. Functional consequences of human induced pluripotent stem cell therapy: myocardial ATP turnover rate in the in vivo swine heart with postinfarction remodeling. Circulation 2013;127(9):997-1008
   PubMed Web of Science ®Google Scholar
• Sanganalmath SK, Bolli R. Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res 2013;113(6):810-34
   PubMed Web of Science ®Google Scholar
• Almeida SO, Skelton RJ, Adigopula S, Ardehali R. Arrhythmia in stem cell transplantation. Card Electrophysiol Clin 2015;7(2):357-70
   Google Scholar
• Kurazumi H, Kubo M, Ohshima M, et al. The effects of mechanical stress on the growth, differentiation, and paracrine factor production of cardiac stem cells. PLoS One 2011;6(12):e28890
   PubMed Web of Science ®Google Scholar
• Lionetti V, Bianchi G, Recchia FA, Ventura C. Control of autocrine and paracrine myocardial signals: an emerging therapeutic strategy in heart failure. Heart Fail Rev 2010;15(6):531-42
   PubMed Web of Science ®Google Scholar
• Shintani Y, Fukushima S, Varela-Carver A, et al. Donor cell-type specific paracrine effects of cell transplantation for post-infarction heart failure. J Mol Cell Cardiol 2009;47(2):288-95
   PubMed Web of Science ®Google Scholar
• Burchfield JS, Dimmeler S. Role of paracrine factors in stem and progenitor cell mediated cardiac repair and tissue fibrosis. Fibrogenesis Tissue Repair 2008;1(1):4
   PubMedGoogle Scholar
• van Berlo JH, Molkentin JD. An emerging consensus on cardiac regeneration. Nat Med 2014;20(12):1386-93
   PubMed Web of Science ®Google Scholar
• Chou SH, Lin SZ, Kuo WW, et al. Mesenchymal stem cell insights: prospects in cardiovascular therapy. Cell Transplant 2014;23(4-5):513-29
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A, et al. Intracoronary bone marrow-derived progenitor cells in acute myocardial infarction. N Engl J Med 2006;355(12):1210-21
   PubMed Web of Science ®Google Scholar
• Schachinger V, Erbs S, Elsasser A, et al. Improved clinical outcome after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Eur Heart J 2006;27(23):2775-83
   PubMed Web of Science ®Google Scholar
• Tendera M, Wojakowski W, Ruzyllo W, et al. Intracoronary infusion of bone marrow-derived selected CD34+CXCR4+ cells and non-selected mononuclear cells in patients with acute STEMI and reduced left ventricular ejection fraction: results of randomized, multicentre Myocardial Regeneration by Intracoronary Infusion of Selected Population of Stem Cells in Acute Myocardial Infarction (REGENT) Trial. Eur Heart J 2009;30(11):1313-21
   PubMed Web of Science ®Google Scholar
• Schwartz SD, Hubschman JP, Heilwell G, et al. Embryonic stem cell trials for macular degeneration: a preliminary report. Lancet 2012;379(9817):713-20
   PubMed Web of Science ®Google Scholar
• Hulot JS, Stillitano F, Salem JE, et al. Considerations for pre-clinical models and clinical trials of pluripotent stem cell-derived cardiomyocytes. Stem Cell Res Ther 2014;5(1):1
   PubMedGoogle Scholar
• Hattori F, Chen H, Yamashita H, et al. Nongenetic method for purifying stem cell-derived cardiomyocytes. Nat Methods 2010;7(1):61-6
   PubMed Web of Science ®Google Scholar
• Zhao T, Zhang ZN, Rong Z, Xu Y. Immunogenicity of induced pluripotent stem cells. Nature 2011;474(7350):212-15
   PubMed Web of Science ®Google Scholar
• Turnbull IC, Karakikes I, Serrao GW, et al. Advancing functional engineered cardiac tissues toward a preclinical model of human myocardium. FASEB J 2014;28(2):644-54
   PubMed Web of Science ®Google Scholar
• Hirt MN, Hansen A, Eschenhagen T. Cardiac tissue engineering: state of the art. Circ Res 2014;114(2):354-67
   PubMed Web of Science ®Google Scholar
• Agency EM. Reflection paper on stem cell-based medicinal products. 2011
   Google Scholar
• Unger C, Skottman H, Blomberg P, et al. Good manufacturing practice and clinical-grade human embryonic stem cell lines. Hum Mol Genet 2008;17(R1):R48-53
   PubMedGoogle Scholar
• Silva M, Daheron L, Hurley H, et al. Generating iPSCs: translating cell reprogramming science into scalable and robust biomanufacturing strategies. Cell Stem Cell 2015;16(1):13-17
   PubMed Web of Science ®Google Scholar